secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-07-24T12:03:32+00:00
Accession:  0001193125-26-315163
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma and Menarini receive positive CHMP opinion for obicetrapib products in Europe
--------------------------------------------------------------------------------

- CHMP recommends marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib/ezetimibe FDC) for hypercholesterolemia.
- Recommendation based on Phase 3 BROADWAY, BROOKLYN, and TANDEM trials showing LDL-C reductions up to 40-50% vs placebo.
- European Commission final decision expected in 2H26; if approved, authorization applies across EU plus Iceland, Liechtenstein, Norway.
- Menarini holds exclusive European commercialization rights; NewAmsterdam eligible for tiered double-digit royalties and up to €833M in milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526315163/0001193125-26-315163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526315163/nams-20260724.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-315163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer